Funding

BrainChild Bio

United States · Biotech

BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma.

Visit brainchildbio.comFunding history

Product and customers

Its approach engineers immune cells to target tumor antigens and delivers repeat infusions locally into cerebrospinal fluid through an implanted reservoir, aiming to reach tumors behind the blood-brain barrier. The company is clinical-stage, with BCB-276 in a Phase 2 study and additional candidates in development.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A$116MParticipants not disclosed

Investors

No participants disclosed.

Coverage

Sep 8, 2026BrainChild Bio · Series A

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesbrainchildbio.com ↗brainchildbio.com ↗